WO2007119001A3 - Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique - Google Patents

Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique Download PDF

Info

Publication number
WO2007119001A3
WO2007119001A3 PCT/FR2007/000620 FR2007000620W WO2007119001A3 WO 2007119001 A3 WO2007119001 A3 WO 2007119001A3 FR 2007000620 W FR2007000620 W FR 2007000620W WO 2007119001 A3 WO2007119001 A3 WO 2007119001A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl group
group
phenyl
therapeutic use
pyridine derivatives
Prior art date
Application number
PCT/FR2007/000620
Other languages
English (en)
Other versions
WO2007119001A2 (fr
Inventor
Francis Barth
Christian Congy
Philippe Pointeau
Murielle Rinaldi-Carmona
Lionel Barre
Original Assignee
Sanofi Aventis
Francis Barth
Christian Congy
Philippe Pointeau
Murielle Rinaldi-Carmona
Lionel Barre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Francis Barth, Christian Congy, Philippe Pointeau, Murielle Rinaldi-Carmona, Lionel Barre filed Critical Sanofi Aventis
Priority to MX2008013208A priority Critical patent/MX2008013208A/es
Priority to AU2007239344A priority patent/AU2007239344A1/en
Priority to CA002645961A priority patent/CA2645961A1/fr
Priority to JP2009504782A priority patent/JP2009533400A/ja
Priority to BRPI0710741-2A priority patent/BRPI0710741A2/pt
Priority to EP07731288A priority patent/EP2010492A2/fr
Publication of WO2007119001A2 publication Critical patent/WO2007119001A2/fr
Publication of WO2007119001A3 publication Critical patent/WO2007119001A3/fr
Priority to IL194573A priority patent/IL194573A0/en
Priority to US12/249,140 priority patent/US20090203699A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)

Abstract

La présente invention a pour objet des composés répondant à la formule : (I) dans laquelle : Z représente un groupe N(R3)XR4, N(R3)COOR5 ou OCON(R3)R5; X représente un groupe -CO-, -SO2-, -CON(R6)- ou CSN(R6)-; - R1 et R2 représentent chacun indépendamment l'un de l'autre un atome d'hydrogène ou un (C1-C7)alkyle ou ensemble avec l'atome d'azote auquel ils sont liés constituent un radical hétérocyclique saturé ou insaturé; R3 et Rg représente un atome d'hydrogène ou un groupe (C1-C4)alkyle; - R4 représente :. un groupe (C3-C10)alkyle \ un radical carbocyclique; un radical hétérocyclique; un indolyle; un tétrahydronaphtalényle, un naphtalényle; un benzothiophényle ou un benzoruryle; un phényle; un benzodioxyle; un phénoxyméthylène, un 1-phénoxyéthylène; un phénylcyclopropyle; R5 représente un phényle; A1 et Ar2 représentent chacun indépendamment l'un de l'autre un phényle non substitué ou substitué; n représente 0, 1 ou 2; AIk représente un groupe (C1-C7)alkyle; à l'état de base ou de sel d'addition, ainsi qu'à l'état d'hydrate ou de solvat.
PCT/FR2007/000620 2006-04-14 2007-04-12 Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique WO2007119001A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2008013208A MX2008013208A (es) 2006-04-14 2007-04-12 Derivados de aminometilpiridina, su preparacion y su aplicacion en terapeutica.
AU2007239344A AU2007239344A1 (en) 2006-04-14 2007-04-12 Aminomethyl pyridine derivatives, method for preparing same and therapeutic use thereof
CA002645961A CA2645961A1 (fr) 2006-04-14 2007-04-12 Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique
JP2009504782A JP2009533400A (ja) 2006-04-14 2007-04-12 アミノメチルピリジン誘導体、この調製方法、およびこの治療的使用
BRPI0710741-2A BRPI0710741A2 (pt) 2006-04-14 2007-04-12 derivado de amino metil piridina, o respectivo preparo e a respectiva aplicação em terapêutica
EP07731288A EP2010492A2 (fr) 2006-04-14 2007-04-12 Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique
IL194573A IL194573A0 (en) 2006-04-14 2008-10-06 Aminomethyl pyridine derivatives, method for preparing same and therapeutic use thereof
US12/249,140 US20090203699A1 (en) 2006-04-14 2008-10-10 Aminomethylpyridine derivatives, method for preparing same and therapeutic use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0603382A FR2899899A1 (fr) 2006-04-14 2006-04-14 Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
FR0603382 2006-04-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/249,140 Continuation US20090203699A1 (en) 2006-04-14 2008-10-10 Aminomethylpyridine derivatives, method for preparing same and therapeutic use thereof

Publications (2)

Publication Number Publication Date
WO2007119001A2 WO2007119001A2 (fr) 2007-10-25
WO2007119001A3 true WO2007119001A3 (fr) 2007-12-13

Family

ID=37434008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/000620 WO2007119001A2 (fr) 2006-04-14 2007-04-12 Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique

Country Status (18)

Country Link
US (1) US20090203699A1 (fr)
EP (1) EP2010492A2 (fr)
JP (1) JP2009533400A (fr)
KR (1) KR20080108540A (fr)
CN (1) CN101421240A (fr)
AR (1) AR060800A1 (fr)
AU (1) AU2007239344A1 (fr)
BR (1) BRPI0710741A2 (fr)
CA (1) CA2645961A1 (fr)
DO (1) DOP2007000067A (fr)
FR (1) FR2899899A1 (fr)
IL (1) IL194573A0 (fr)
MX (1) MX2008013208A (fr)
PE (1) PE20071224A1 (fr)
RU (1) RU2008144952A (fr)
TW (1) TW200813037A (fr)
UY (1) UY30285A1 (fr)
WO (1) WO2007119001A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
CN103003242B (zh) * 2010-07-20 2015-04-22 科学与工业研究委员会 吡啶-2-基硫基酸酯及其制备方法
GB201103419D0 (fr) 2011-02-28 2011-04-13 Univ Aberdeen
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916905A (en) * 1995-02-10 1999-06-29 G. D. Searle & Co. 2,3-substituted pyridines for the treatment of inflammation
WO2003082191A2 (fr) * 2002-03-28 2003-10-09 Merck & Co., Inc. 2,3-diphenyl-pyridines substituees
WO2003084930A1 (fr) * 2002-04-11 2003-10-16 Sanofi-Synthelabo Derives de diphenylpyridine, leur preparation, les compositions pharmaceutiques en contenant
WO2003084943A2 (fr) * 2002-04-11 2003-10-16 Sanofi-Aventis Derives de terphenyle, leur preparation, les compositions pharmaceutiques en contenant
WO2005000817A2 (fr) * 2003-06-26 2005-01-06 Sanofi-Aventis Derives de diphenylpyridine, leur preparation et leur application en therapeutique
WO2005073197A1 (fr) * 2004-01-12 2005-08-11 Sanofi-Aventis Derives de n-` (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1
WO2006042955A1 (fr) * 2004-10-18 2006-04-27 Sanofi-Aventis Derives de pyridine, leur preparation, leur application en therapeutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5481005A (en) * 1990-07-31 1996-01-02 Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916905A (en) * 1995-02-10 1999-06-29 G. D. Searle & Co. 2,3-substituted pyridines for the treatment of inflammation
WO2003082191A2 (fr) * 2002-03-28 2003-10-09 Merck & Co., Inc. 2,3-diphenyl-pyridines substituees
WO2003084930A1 (fr) * 2002-04-11 2003-10-16 Sanofi-Synthelabo Derives de diphenylpyridine, leur preparation, les compositions pharmaceutiques en contenant
WO2003084943A2 (fr) * 2002-04-11 2003-10-16 Sanofi-Aventis Derives de terphenyle, leur preparation, les compositions pharmaceutiques en contenant
WO2005000817A2 (fr) * 2003-06-26 2005-01-06 Sanofi-Aventis Derives de diphenylpyridine, leur preparation et leur application en therapeutique
WO2005073197A1 (fr) * 2004-01-12 2005-08-11 Sanofi-Aventis Derives de n-` (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1
WO2006042955A1 (fr) * 2004-10-18 2006-04-27 Sanofi-Aventis Derives de pyridine, leur preparation, leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADAMS J ET AL: "Recent advances in the cannabinoids", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 12, no. 10, 2002, pages 1475 - 1489, XP002353808, ISSN: 1354-3776 *

Also Published As

Publication number Publication date
AR060800A1 (es) 2008-07-16
BRPI0710741A2 (pt) 2011-06-07
AU2007239344A1 (en) 2007-10-25
KR20080108540A (ko) 2008-12-15
MX2008013208A (es) 2008-10-27
IL194573A0 (en) 2009-09-22
WO2007119001A2 (fr) 2007-10-25
RU2008144952A (ru) 2010-05-20
EP2010492A2 (fr) 2009-01-07
FR2899899A1 (fr) 2007-10-19
UY30285A1 (es) 2007-11-30
JP2009533400A (ja) 2009-09-17
TW200813037A (en) 2008-03-16
CN101421240A (zh) 2009-04-29
US20090203699A1 (en) 2009-08-13
PE20071224A1 (es) 2008-01-23
DOP2007000067A (es) 2007-10-31
CA2645961A1 (fr) 2007-10-25

Similar Documents

Publication Publication Date Title
WO2007119001A3 (fr) Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique
MY145031A (en) N-(aminoheteroaryl)-1h-indole-2carboxamide derivatives, and preparation and therapeutic application thereof
TN2009000081A1 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2- α ] PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
MY150289A (en) Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof
WO2005118557A3 (fr) Composes organiques
WO2005118541A3 (fr) Composes organiques
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
WO2008081096A3 (fr) Derives quinolinyliques, leur procede de preparation. les compositions pharmaceutiques qui les contiennent et leur utilisation comme agents hypoglycemiants et hypoli pemiants
WO2008120725A1 (fr) Nouveau dérivé de pyrrolinone et composition médicale le contenant
NO20076006L (no) Acetylenderivater
NO20074391L (no) CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
WO2006005726A3 (fr) Composes organiques
NO20075626L (no) Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
NO20070089L (no) DPP-IV inhibitorer
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
NO20071658L (no) Alkil-pyridiner som 11-beta-inhibitorer for diabetes
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
FR2894578B1 (fr) Derives heterocycliques, leur preparation et leur application en therapeutique.
NO20092066L (no) Pyrrolderivater, fremgangsmate for fremstilling og terapeutisk anvendelse derav
SE0403086D0 (sv) Compounds
FR2894579B1 (fr) Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2645961

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007731288

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 194573

Country of ref document: IL

Ref document number: 4056/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009504782

Country of ref document: JP

Ref document number: 2007239344

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/013208

Country of ref document: MX

Ref document number: 200780013170.1

Country of ref document: CN

Ref document number: 1020087024954

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07731288

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2007239344

Country of ref document: AU

Date of ref document: 20070412

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008144952

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0710741

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081014